Circulating CD5L is associated with cardiovascular events and all-cause mortality in individuals with chronic kidney disease

Show full item record



Permalink

http://hdl.handle.net/10138/336989

Citation

Castelblanco , E , Sarrias , M R , Betriu , A , Soldevila , B , Barranco-Altirriba , M , Franch-Nadal , J , Valdivielso , J M , Bermudez-Lopez , M , Groop , P-H , Fernandez , E , Alonso , N & Mauricio , D 2021 , ' Circulating CD5L is associated with cardiovascular events and all-cause mortality in individuals with chronic kidney disease ' , Aging , vol. 13 , no. 19 , pp. 22690-22709 . < http://10.18632/aging.203615 >

Title: Circulating CD5L is associated with cardiovascular events and all-cause mortality in individuals with chronic kidney disease
Author: Castelblanco, Esmeralda; Sarrias, Maria R.; Betriu, Angels; Soldevila, Berta; Barranco-Altirriba, Maria; Franch-Nadal, Josep; Valdivielso, Jose M.; Bermudez-Lopez, Marcelino; Groop, Per-Henrik; Fernandez, Elvira; Alonso, Nuria; Mauricio, Didac
Contributor organization: HUS Abdominal Center
Research Programs Unit
Department of Medicine
Per Henrik Groop / Principal Investigator
Clinicum
Nefrologian yksikkö
CAMM - Research Program for Clinical and Molecular Metabolism
Date: 2021-10-15
Language: eng
Number of pages: 20
Belongs to series: Aging
ISSN: 1945-4589
URI: http://hdl.handle.net/10138/336989
Abstract: This study assessed the association of CD5L and soluble CD36 (sCD36) with the risk of a cardiovascular event (CVE), including CV death and all-cause mortality in CKD. We evaluated the association of CD5L and sCD36 with a predefined composite CV endpoint (unstable angina, myocardial infarction, transient ischemic attack, cerebrovascular accident, congestive heart failure, arrhythmia, peripheral arterial disease [PAD] or amputation by PAD, aortic aneurysm, or death from CV causes) and all-cause mortality using Cox proportional hazards regression, adjusted for CV risk factors. The analysis included 1,516 participants free from pre-existing CV disease followed up for 4 years. The median age was 62 years, 38.8% were female, and 26.8% had diabetes. There were 98 (6.5%) CVEs and 72 (4.8%) deaths, of which 26 (36.1%) were of CV origin. Higher baseline CD5L concentration was associated with increased risk of CVE (HR, 95% CI, 1.17, 1.0-1.36), and all-cause mortality (1.22, 1.01-1.48) after adjusting for age, sex, diabetes, systolic blood pressure, dyslipidemia, waist circumference, smoking, and CKD stage. sCD36 showed no association with adverse CV outcomes or mortality. Our study showed for the first time that higher concentrations of CD5L are associated with future CVE and all -cause mortality in individuals with CKD.
Subject: CD5L
sCD36
chronic kidney disease
cardiovascular events
mortality
GLOMERULAR-FILTRATION-RATE
APOPTOSIS INHIBITOR
PLASMA SCD36
SOLUBLE CD36
RISK
ATHEROSCLEROSIS
AIM
MACROPHAGES
PROGRESSION
BIOMARKERS
1182 Biochemistry, cell and molecular biology
3121 General medicine, internal medicine and other clinical medicine
Peer reviewed: Yes
Rights: cc_by
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
aging_v13i19_203615.pdf 938.1Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record